Comparison 9. Sunitinib versus IMA901 + Sunitinib.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
9.1 Progression‐free survival	1		Hazard Ratio (IV, Random, 95% CI)	Totals not selected
9.2 Overall survival	1		Hazard Ratio (IV, Random, 95% CI)	Totals not selected
9.3 Serious adverse events (Grade 3 or 4)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
9.4 Response rate	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
9.5 Minor adverse events (Grade 1 or 2)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected